New shot therapy targets tough skin cancers
NCT ID NCT07227870
First seen Nov 15, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This study tests a new treatment for people with advanced basal cell skin cancer that has stopped responding to or cannot tolerate standard therapies. The treatment is a combination of two drugs (L19IL2 and L19TNF) injected directly into the tumors once a week for up to 8 weeks. The goal is to see if the tumors shrink or disappear, and to check for side effects. About 92 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa, Florida, 33612, United States
Contact
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States
Contact
Conditions
Explore the condition pages connected to this study.